From ClinicalTrials.gov
GLP-1 clinical trial results
220 Phase 3 trials with posted results, 131 of them named. Each page shows the results and side effects arm by arm, as the registry posts them. The newest update at source is Nov 4, 2026.
Largest first
Trials with results
220 trials, 209,536 participants.
| Trial | Medication | People | Primary result |
|---|---|---|---|
| SELECTSemaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity | Semaglutide | 17,604 | Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke (Participants), From randomisation (week 0) up to 240 weeks. Semaglutide: 569; Placebo: 701. |
| NCT01144338Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus | Exenatide | 14,752 | Primary Efficacy Outcome MACE Events (Participants), Time to first event. Information collected during study period (anticipated to be up to 7.5 years).. Placebo: 905; Exenatide Once Weekly: 839. |
| SURPASS-CVOTA Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes | Dulaglutide | 13,299 | Number of Participants From Randomization to First Occurrence of Death From MACE-3 [Composite Endpoint of Major Adverse Cardiovascular Events Death From Cardiovascular Causes, Myocardial Infarction (MI) or Stroke] (participants), From randomization (week 0) up to week 259. Tirzepatide (MTD): 801; 1.5 mg Dulaglutide: 862. |
| REWINDResearching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) | Dulaglutide | 9,901 | Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (Participants), From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years). Placebo: 663; Dulaglutide: 594. |
| SOULA Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes | Semaglutide | 9,651 | Number of Participants From Randomization to First Occurrence of a Major Adverse Cardiovascular Event (MACE), a Composite Endpoint Consisting of: Cardiovascular (CV) Death/Non-fatal Myocardial Infarction/Non-fatal Stroke (Participants), From randomisation (week 0) up to week 265. Oral Semaglutide: 579; Placebo: 668. |
| LEADERLiraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results | Liraglutide | 9,341 | Time From Randomisation to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (percentage of subjects), from randomisation (visit 3; month 0) to last contact (visit 16; up to month 60+30 days). Liraglutide: 13.0; Placebo: 14.9. |
| GRADEA Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes | Liraglutide | 7,850 | Time to HbA1c>=7%, While Receiving Metformin and the Randomly Assigned Glucose-lowering Study Medication (years), Quarterly for 4 to 7 years. Glargine Insulin U-100: 1.3; Glimepiride: 1.3; Liraglutide: 1.5; Sitagliptin: 0.8. |
| NCT01272219Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes | Liraglutide | 3,731 | Change From Baseline in Fasting Body Weight (percent change), Week 0, Week 56. Liraglutide 3.0 mg (56-Week): -7.98; Liraglutide Placebo (56-Week): -2.62. |
| FLOWA Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease | Semaglutide | 3,533 | Number of Participants From Time of Randomization to First Occurrence of Onset of Persistent ≥50% Reduction in eGFR(CKD-EPI); Onset of Persistent eGFR(CKD-EPI) <15mL/Min/1.73m^2; Initiation of Chronic Renal Replacement Therapy; Renal Death; CV Death (Participants), From Week 0 up to Week 234. Semaglutide: 331; Placebo: 410. |
| SUSTAIN 6Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes | Semaglutide | 3,297 | Time From Randomisation to First Occurrence of a MACE, Defined as Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (percentage of subjects), Time from randomisation up to end of follow-up (scheduled at week 109). Semaglutide: 6.6; Placebo: 8.9. |
| ATTAIN-1A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities | Orforglipron | 3,127 | Percent Change From Baseline in Body Weight (Primary Treatment Period) (percent change), Baseline, Week 72. Placebo: -0.87; 6 mg Orforglipron: -7.82; 12 mg Orforglipron: -9.27; 36 mg Orforglipron: -12.35. |
| SURMOUNT-1A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight | Tirzepatide | 2,539 | Percent Change From Baseline in Body Weight (Primary Treatment Period) (percent change), Baseline, Week 72. Placebo: -2.4; 5 mg Tirzepatide: -16.0; 10 mg Tirzepatide: -21.4; 15 mg Tirzepatide: -22.5. |
| SUSTAIN 11A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes | Semaglutide | 2,274 | Change From Baseline in Glycated Haemoglobin (HbA1c) (Percentage of HbA1c), Baseline (week 0), week 52. Semaglutide: -1.5; Insulin Aspart: -1.2. |
| SURPASS-4A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk | Tirzepatide | 2,002 | Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg) (Percentage of HbA1c), Baseline, Week 52. 10 mg Tirzepatide: -2.43; 15 mg Tirzepatide: -2.58; Insulin Glargine: -1.44. |
| STEP 1STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity | Semaglutide | 1,961 | See the trial's page: several measures or groups. |
| SURPASS-2A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes | Semaglutide | 1,879 | Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg) (Percentage of HbA1c), Baseline, Week 40. 10 mg Tirzepatide: -2.37; 15 mg Tirzepatide: -2.46; 1 mg Semaglutide: -1.86. |
| PIONEER 3Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes | Semaglutide | 1,864 | See the trial's page: several measures or groups. |
| AWARD-11A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes | Dulaglutide | 1,842 | Change in Hemoglobin A1c (HbA1c) From Baseline (Percentage of HbA1c), Baseline, Week 36. Dulaglutide 1.5 mg: -1.53; Dulaglutide 3 mg: -1.71; Dulaglutide 4.5 mg: -1.87. |
| ACHIEVE-3A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin | Orforglipron | 1,698 | Change From Baseline in Hemoglobin A1c (HbA1c) [Non-inferiority of 36 mg Orforglipron Versus 14 mg Semaglutide and 12 mg Orforglipron Versus 7 mg Semaglutide] (Percentage of HbA1c), Baseline, Week 52. 12 mg Orforglipron: -1.91; 36 mg Orforglipron: -2.16; 7 mg Semaglutide: -1.11; 14 mg Semaglutide: -1.45. |
| DUAL IDual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes | Liraglutide | 1,663 | Mean Change From Baseline in HbA1c (Glycosylated Haemoglobin) at Week 26. (Percentage of glycosylated haemoglobin), Week 0, week 26. IDeg: -1.44; IDegLira: -1.91; Liraglutide: -1.28. |
| ATTAIN-2A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes | Orforglipron | 1,613 | Percent Change From Baseline in Body Weight (percent change), Baseline, Week 72. Placebo: -2.21; 6 mg Orforglipron QD: -5.50; 12 mg Orforglipron QD: -7.78; 36 mg Orforglipron QD: -10.54. |
| PIONEER PLUSResearch Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes | Semaglutide | 1,606 | Change From Baseline in Glycated Haemoglobin (HbA1c) (Week 52) (Percentage point of HbA1c), Baseline (week 0), week 52. Oral Semaglutide 14 mg: -1.5; Oral Semaglutide 25 mg: -1.9; Oral Semaglutide 50 mg: -2.1. |
| SURPASS-3A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes | Tirzepatide | 1,444 | Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg) (Percentage of HbA1c), Baseline, Week 52. 10 mg Tirzepatide: -2.20; 15 mg Tirzepatide: -2.37; Insulin Degludec: -1.34. |
| PIONEER 12A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes | Semaglutide | 1,441 | See the trial's page: several measures or groups. |
| SURPASS-6A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin | Tirzepatide | 1,428 | Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg, 10 mg and 15 mg) (Percentage of HbA1c), Baseline, Week 52. Pooled 5 mg/10 mg/15 mg Tirzepatide: -2.26; Insulin Lispro: -1.16. |
| STEP UPA Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP) | Semaglutide | 1,407 | Semaglutide 7.2 mg Versus Placebo: Relative Change in Body Weight (Percentage (%) change in body weight), Baseline (week 0), End of treatment (week 72). Semaglutide 7.2 mg: -19.5; Placebo: -3.8. |
| ADJUNCT ONEThe Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes | Liraglutide | 1,398 | Change From Baseline in HbA1c (Glycosylated Haemoglobin) (percentage of glycosylated haemoglobin), Week 0, week 52. Liraglutide 0.6 mg: -0.45; Liraglutide 1.2 mg: -0.50; Liraglutide 1.8 mg: -0.54; Placebo: -0.34. |
| COMBINE 1A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec | Semaglutide | 1,291 | Change in Glycated Haemoglobin (HbA1c) (Percentage point of HbA1c), Baseline (Week 0), Week 52. IcoSema: -1.60; Insulin Icodec: -0.90. |
| SUSTAIN 2Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes | Semaglutide | 1,231 | Change in HbA1c (Glycosylated Haemoglobin) From Baseline (percentage of glycosylated haemoglobin), Week 0, week 56. Semaglutide 0.5 mg + Sitagliptin Placebo: -1.32; Semaglutide 1.0 mg + Sitagliptin Placebo: -1.61; Sitagliptin + Semaglutide Placebo: -0.55. |
| STEP 2Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity | Semaglutide | 1,210 | See the trial's page: several measures or groups. |
| NCT00734474A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin | Dulaglutide | 1,202 | Glycosylated Hemoglobin (HbA1c) Change From Baseline (percentage of HbA1c), Baseline, 52 weeks. 1.5 mg LY2189265: -1.10; 0.75 mg LY2189265: -0.87; Sitagliptin: -0.39. |
| SUSTAIN 7Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes. | Dulaglutide | 1,201 | Change in HbA1c (percentage of HbA1c), Week 0, week 40. Semaglutide 0.5 mg: -1.51; Semaglutide 1.0 mg: -1.78; Dulaglutide 0.75 mg: -1.11; Dulaglutide 1.5 mg: -1.37. |
| LEAD-2To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together | Liraglutide | 1,091 | Change in Glycosylated A1c (HbA1c) at Week 26 (Percentage point of total HbA1c), week 0, week 26. Lira 0.6 + Met: -0.69; Lira 1.2 + Met: -0.97; Lira 1.8 + Met: -1.00; Met Mono: 0.09; Met + Glim: -0.98. |
| SUSTAIN 4Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes | Semaglutide | 1,089 | Change in HbA1c From Baseline (percentage), Week 0, week 30. Semaglutide 0.5mg/Week: -1.21; Semaglutide 1.0 mg/Week: -1.64; Insulin Glargine: -0.83. |
| NCT00960661A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes | Exenatide | 1,036 | Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 30 (percent of hemoglobin), Baseline, 30 weeks. Exenatide (BET): -1.13; Insulin Lispro (BBT): -1.10. |
| NCT00359762Exenatide Versus Glimepiride in Patients With Type 2 Diabetes | Exenatide | 1,029 | Time to Treatment Failure (week), Baseline to end of Period II (up to 4.5 years). Exen + Met: 180.0; Glim + Met: 142.1. |
| DUAL VIIIA 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus | Liraglutide | 1,012 | See the trial's page: several measures or groups. |
| NCT00856986The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes | Liraglutide | 987 | Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 26. (Percentage point of total HbA1c), Week 0 (Randomisation), week 26. Lira 1.8: 0.02; Insulin Detemir + Lira 1.8: -0.51. |
| AWARD-1A Study in Participants With Type 2 Diabetes Mellitus | Dulaglutide | 978 | Change From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c) (percentage of glycosylated hemoglobin), Baseline, 26 weeks. 1.5 mg LY2189265: -1.51; 0.75 mg LY2189265: -1.30; Exenatide: -0.99; Placebo: -0.46. |
| ACHIEVE-2A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin | Orforglipron | 962 | Change From Baseline in HbA1c [Noninferiority Analysis] (percentage of HbA1c), Baseline, Week 40. Orforglipron 3 mg: -1.32; Orforglipron 12 mg: -1.74; Orforglipron 36 mg: -1.73; Dapagliflozin 10 mg: -0.76. |
| SUSTAIN FORTEA Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes | Semaglutide | 961 | See the trial's page: several measures or groups. |
| SURMOUNT-2A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight | Tirzepatide | 938 | Percent Change From Baseline in Body Weight (percent change), Baseline, Week 72. Placebo: -3.3; 10 mg Tirzepatide: -13.4; 15 mg Tirzepatide: -15.7. |
| NCT00614120Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes | Liraglutide | 929 | Change in Glycosylated Haemoglobin A1c (HbA1c) (percentage point of total HbA1c), week 0, week 16. Lira 0.6 + Met: -1.0; Lira 1.2 + Met: -1.3; Lira 1.8 + Met: -1.4; Glim + Met: -1.3. |
| NCT04093752A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo) | Tirzepatide | 917 | Mean Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg) (Percentage of HbA1c), Baseline, Week 40. 10 mg Tirzepatide: -2.44; 15 mg Tirzepatide: -2.49; Insulin Glargine: -0.95. |
| NCT01029886Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes | Liraglutide | 912 | Change in HbA1c From Baseline to Week 26 (percentage of total hemoglobin), Baseline, Week 26. Exenatide Once Weekly: -1.28; Liraglutide Once Daily: -1.48. |
| AMPLITUDE-DEfficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin | Dulaglutide | 908 | Change From Baseline to Week 56 in HbA1c (percentage of HbA1c), Baseline to Week 56. Efpeglenatide 4 mg: -1.12; Efpeglenatide 6 mg: -1.17; Dulaglutide 1.5 mg: -1.09. |
| STEP 4Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity | Semaglutide | 902 | See the trial's page: several measures or groups. |
| NCT01191268A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4) | Dulaglutide | 884 | Change From Baseline to 26-week Endpoint in Glycosylated Hemoglobin (HbA1c) (percentage of glycosylated hemoglobin), Baseline, 26 weeks. 1.5 mg LY2189265: -1.64; 0.75 mg LY2189265: -1.59; Insulin Glargine: -1.41. |
| SUSTAINEfficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT) | Semaglutide | 868 | See the trial's page: several measures or groups. |
| NCT01272232Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes | Liraglutide | 846 | Change (%) From Baseline in Body Weight (Fasting) (percent change), Week 0, week 56. Liraglutide 3.0 mg: -5.9; Liraglutide 1.8 mg: -4.6; Liraglutide Placebo: -2.0. |
| NCT01128894A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide. | Liraglutide | 841 | Mean Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 32 (Percentage of HbA1c in the blood), Baseline and Week 32. Albiglutide 50 mg: -0.78; Liraglutide 1.8 mg: -0.99. |
| ADJUNCT TWOThe Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes | Liraglutide | 835 | Change From Baseline in Glycosylated Haemoglobin (HbA1c) (Percent (%) glycosylated haemoglobin), Week 0, Week 26. Liraglutide 0.6 mg: -0.23; Liraglutide 1.2 mg: -0.23; Liraglutide 1.8 mg: -0.32; Liraglutide Placebo: 0.01. |
| PIONEER 2Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus | Semaglutide | 822 | See the trial's page: several measures or groups. |
| NCT00676338Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4) | Exenatide | 820 | Change in HbA1c From Baseline to Week 26 (percentage of total hemoglobin), Baseline, Week 26. Exenatide Once Weekly: -1.53; Metformin: -1.48; Pioglitazone: -1.63; Sitagliptin: -1.15. |
| DUAL I JapanA Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus. | Liraglutide | 819 | Change From Baseline in HbA1c (Glycosylated Haemoglobin) Tested for Non-inferiority of IDegLira vs IDeg and Superiority of IDegLira vs Lira (Percentage of HbA1c), Week 0, Week 52. Insulin Degludec/Liraglutide: -2.42; Insulin Degludec: -1.80; Liraglutide: -1.80. |
| SUSTAIN 3Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes | Semaglutide | 813 | Change From Baseline in HbA1c (Glycosylated Haemoglobin) (percentage of glycosylated haemoglobin), Week 0, week 56. Semaglutide 1.0 mg: -1.54; Exenatide ER 2.0 mg: -0.92. |
| AWARD-2A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2) | Dulaglutide | 810 | Change From Baseline to 52 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c) (percentage of glycosylated hemoglobin), Baseline, 52 weeks. LY2189265 1.5 mg: -1.08; LY2189265 0.75 mg: -0.76; Insulin Glargine: -0.63. |
| NCT01126580A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3) | Dulaglutide | 807 | Change From Baseline to 26-week Endpoint in Glycosylated Hemoglobin (HbA1c) (percentage of glycosylated hemoglobin), Baseline, 26 weeks. 1.5 mg LY2189265: -0.78; 0.75 mg LY2189265: -0.71; Metformin: -0.56. |
| STRIDEA Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes | Semaglutide | 792 | Change in Maximum Walking Distance on a Constant Load Treadmill Test (Ratio of maximum walking distance), Baseline (week 0), end of treatment (week 52). Semaglutide: 1.21; Placebo: 1.08. |
| SUSTAIN 8Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes | Semaglutide | 788 | See the trial's page: several measures or groups. |
| SURMOUNT-4A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss | Tirzepatide | 783 | Percent Change From Randomization in Body Weight at Week 88 (percent change), Randomization (Week 36), Week 88. Placebo: 14.8; Tirzepatide MTD: -6.7. |
| AWARD-CHN2A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus | Dulaglutide | 774 | Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks (percentage of HbA1c), Baseline, 26 Weeks. 1.5 mg Dulaglutide: -1.73; 0.75 mg Dulaglutide: -1.33; Insulin Glargine: -1.16. |
| SURMOUNT-5A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities | Semaglutide | 751 | Percent Change From Baseline in Body Weight (Percent change), Baseline, Week 72. 15 mg or MTD - Tirzepatide: -20.2; 2.4 mg or MTD - Semaglutide: -13.7. |
| LEAD-3To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c | Liraglutide | 746 | Change in Glycosylated Haemoglobin A1c (HbA1c) at Week 52 (percentage point of total HbA1c), week 0, week 52. Lira 1.8: -1.14; Lira 1.2: -0.84; Glimepiride: -0.51. |
| AWARD-CHN1A Study Comparing the Effects and Safety of Dulaglutide With Glimepiride in Type 2 Diabetes Mellitus | Dulaglutide | 737 | Change From Baseline in HbA1c at 26 Weeks (percentage of HbA1c), Baseline, 26 Weeks. 1.5 mg Dulaglutide: -1.48; 0.75 mg Dulaglutide: -1.22; Glimepiride: -0.92. |
| PIONEER 8Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin | Semaglutide | 731 | See the trial's page: several measures or groups. |
| NCT04847557A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial | Tirzepatide | 731 | Change From Baseline in the Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS) (Score on a scale), Baseline, Week 52. Tirzepatide - MTD: 19.51; Placebo: 12.68. |
| DUAL I ChinaA Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) | Liraglutide | 720 | Change in HbA1c (Percentage points of HbA1c), Week 0, week 26. Insulin Degludec/Liraglutide: -1.71; Insulin Degludec: -1.20; Liraglutide: -1.16. |
| PIONEER 4Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus | Liraglutide | 711 | See the trial's page: several measures or groups. |
| PIONEER 1Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only | Semaglutide | 703 | See the trial's page: several measures or groups. |
| NCT02229396Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo | Exenatide | 695 | Change in HbA1c From Baseline to Week 28 (% HbA1c), Baseline to Week 28. Dapagliflozin + Placebo: -1.39; Exenatide + Dapagliflozin: -1.98; Exenatide + Placebo: -1.60. |
| NCT00917267A Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control and Safety in Asian Subjects | Exenatide | 691 | Change in HbA1c From Baseline to Week 26. (percentage of total hemoglobin), Baseline, Week 26. Exenatide Once Weekly: -1.43; Exenatide Twice Daily: -1.12. |
| COMBINE 2A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2) | Semaglutide | 683 | Change From Baseline in Glycosylated Haemoglobin (HbA1c) (Percentage point of HbA1c), Baseline (week 0), (week 52). IcoSema: -1.40; Semaglutide: -0.86. |
| OASIS 1Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1) | Semaglutide | 667 | Percentage Change in Body Weight (Percentage (%) change in body weight), Baseline (week 0), end-of-treatment (week 68). Oral Semaglutide 50 mg: -15.8; Placebo: -2.2. |
| NCT00700817The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus | Liraglutide | 665 | Mean Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 26 (Percentage point of total HbA1c), Week 0, Week 26. Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg: -1.24; Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg: -1.5; Sita -> Sita: -0.9. |
| NCT01296412Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403) | Liraglutide | 653 | Change From Baseline in Hemoglobin A1c (A1C) (percent), Baseline and Week 26. Sitagliptin +/- Glimepiride: -1.32; Liraglutide: -1.42. |
| GETGOAL-XGLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin | Exenatide | 639 | Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 (percentage of hemoglobin), Baseline, Week 24. Lixisenatide: -0.79; Exenatide: -0.96. |
| SURPASS J-monoA Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes | Dulaglutide | 636 | Change From Baseline in Hemoglobin A1c (HbA1c) (percentage of HbA1c), Baseline, Week 52. 5 mg Tirzepatide: -2.37; 10 mg Tirzepatide: -2.55; 15 mg Tirzepatide: -2.82; 0.75 mg Dulaglutide: -1.29. |
| NCT02505334A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus. | Liraglutide | 635 | Change in Glycosylated Haemoglobin (HbA1c) (Week 26) (Percentage (%) of HbA1c), Week 0, Week 26. Liraglutide 1.8 mg: -0.23; Liraglutide 0.9 mg: 0.17. |
| STEP HFpEF DMResearch Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes | Semaglutide | 617 | Change in KCCQ (Kansas City Cardiomyopathy Questionnaire) Clinical Summary Score (Score on a scale), Baseline (week 0), end of treatment (week 52). Semaglutide 2.4 mg: 14.4; Placebo: 7.6. |
| STEP 3Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program | Semaglutide | 611 | See the trial's page: several measures or groups. |
| SUSTAINA Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes | Semaglutide | 601 | Number of Treatment Emergent Adverse Events (TEAEs) (Number of events), Weeks 0-56. Semaglutide 0.5 mg: 909; Semaglutide 1.0 mg: 954; Additional OAD: 269. |
| AWARD-6A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes | Dulaglutide | 599 | Change From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c) (percentage of glycosylated hemoglobin), Baseline, 26 Weeks. 1.5 mg LY2189265: -1.42; 1.8 mg Liraglutide: -1.36. |
| AWARD-JPNA Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes | Dulaglutide | 591 | Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26 (Percentage of HbA1c), Baseline, Week 26. Dulaglutide 1.5 mg: -1.53; Dulaglutide 0.75 mg: -1.25. |
| SURMOUNT-3A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program | Tirzepatide | 579 | Percent Change From Baseline in Body Weight (Percent change), Baseline, 72 Weeks. Placebo: 3.3; Tirzepatide: -21.1. |
| AWARD-7A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD) | Dulaglutide | 577 | Change From Baseline in Hemoglobin A1c (HbA1c) (percentage of HbA1c), Baseline, 26 Weeks. Insulin Glargine: -1.13; Dulaglutide 0.75 mg: -1.12; Dulaglutide 1.5 mg: -1.19. |
| SUSTAIN 10Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes | Semaglutide | 577 | Change in HbA1c (Percentage of glycosylated haemoglobin), Week 0, week 30. Semaglutide 1.0 mg: -1.7; Liraglutide 1.2 mg: -1.1. |
| NCT05514535A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE) | Semaglutide | 573 | Change in Glycated Haemoglobin (HbA1c) [Noninferiority] (Percentage point of HbA1c), From baseline (week 0) to end of treatment (week 40). Insuline Glargine U100 (Reduced) + Semaglutide: -1.37; Insuline Glargine U100 (Titrated): -0.65. |
| ACHIEVE-1A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone | Orforglipron | 559 | Change From Baseline in HbA1c (percentage of HbA1c), Baseline, Week 40. Placebo: -0.15; 3 mg Orforglipron: -1.26; 12 mg Orforglipron: -1.59; 36 mg Orforglipron: -1.45. |
| DUAL VA Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus | Liraglutide | 557 | Change From Baseline in HbA1c (Glycosylated Haemoglobin) (Percentage (%)), Week 0, week 26. Insulin Degludec/Liraglutide (IDegLira): -1.81; Insulin Glargine (IGlar): -1.13. |
| NCT00082381Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin | Exenatide | 551 | See the trial's page: several measures or groups. |
| ACHIEVE-5A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor | Orforglipron | 546 | Change From Baseline in Hemoglobin A1c (HbA1c) (percentage of HbA1c), Baseline, Week 40. Placebo: -0.77; 3 mg Orforglipron QD: -1.54; 12 mg Orforglipron QD: -2.05; 36 mg Orforglipron QD: -1.90. |
| STEP-HFpEFResearch Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity | Semaglutide | 529 | Change in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) (Score on a scale), From baseline (week 0) to end of treatment (week 52). Semaglutide 2.4 mg: 16.8; Placebo: 10.3. |
| PIONEER 11A Research Study Comparing a New Medicine Oral Semaglutide to Placebo in People With Type 2 Diabetes | Semaglutide | 521 | Change From Baseline in Glycosylated Haemoglobin (HbA1c) (Percentage of HbA1c), Baseline (Week 0), Week 26. Oral Semaglutide 3 mg: -1.1; Oral Semaglutide 7 mg: -1.5; Oral Semaglutide 14 mg: -1.6; Placebo: -0.2. |
| NCT00637273A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2) | Exenatide | 514 | Change in HbA1c From Baseline to Week 26 (percentage of total hemoglobin), Day 1, Week 26. Exenatide Once Weekly: -1.55; Sitagliptin: -0.92; Pioglitazone: -1.23. |
| LixiLan-GEfficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period | Liraglutide | 514 | Change From Baseline in Glycated Hemoglobin (HbA1c) to Week 26: Core Period (percentage of HbA1c), Baseline, Week 26. Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC): -1.02; GLP-1 Receptor Agonist: -0.38. |
| NCT05649137A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight | Semaglutide | 512 | Relative Change in Body Weight (Percentage (%) change in body weight), Baseline (week 0), End of treatment (week 72). Semaglutide 7.2 mg: -13.5; Semaglutide 2.4 mg: -10.7; Placebo: -4.0. |
| NCT02420262A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus | Liraglutide | 506 | Change in HbA1c (Glycosylated Haemoglobin) (Percentage of glycosylated haemoglobin), Week 0, Week 26. IDegLira: -1.48; IGlar + IAsp: -1.46. |
| NCT00082407Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin | Exenatide | 505 | See the trial's page: several measures or groups. |
| PIONEER 7Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus. | Semaglutide | 504 | See the trial's page: several measures or groups. |
| NCT00434954Effect of Exenatide Plus Metformin vs. Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Type 2 Diabetes | Exenatide | 494 | Change in Glycosylated Hemoglobin (HbA1c) (Percentage of glycosylated hemoglobin), Baseline and 26 weeks. Exenatide Twice Daily: -1.00; Premixed Insulin Aspart Twice Daily: -1.14. |
| NCT01733758A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM) | Liraglutide | 494 | Model-adjusted Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 (Percentage of HbA1c in the blood), Baseline and Week 24. Placebo: 0.25; Albiglutide 30 mg Weekly: -1.10; Albiglutide 50 mg Weekly: -1.30. |
| NCT01558271A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus | Dulaglutide | 492 | Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks (percentage of HbA1c), Baseline, 26 weeks. LY2189265: -1.43; Placebo: 0.14; Liraglutide: -1.33. |
| SURPASS-1A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone | Tirzepatide | 478 | Change From Baseline in Hemoglobin A1c (HbA1c) (Percentage of HbA1c), Baseline, Week 40. 5 mg Tirzepatide: -1.87; 10 mg Tirzepatide: -1.89; 15 mg Tirzepatide: -2.07; Placebo: 0.04. |
| SURPASS-5A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin | Tirzepatide | 475 | Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg) (Percentage of HbA1c), Baseline, Week 40. 10 mg Tirzepatide: -2.59; 15 mg Tirzepatide: -2.59; Placebo: -0.93. |
| SURMOUNT-OSAObstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea | Tirzepatide | 469 | Change From Baseline in Apnea-Hypopnea Index (AHI) (events per hour), Baseline, Week 52. Tirzepatide MTD_GPI1: -25.25; Placebo_GPI1: -5.25; Tirzepatide MTD_GPI2: -29.27; Placebo_GPI2: -5.51. |
| LEAD-6Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes | Liraglutide | 467 | Change in Glycosylated A1c (HbA1c) at Week 26 (percentage point of total HbA1c), week 0, week 26. Liraglutide -> Liraglutide -> Liraglutide: -1.12; Exenatide -> Liraglutide -> Liraglutide: -0.79. |
| NCT00641056Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3) | Exenatide | 467 | Change in HbA1c From Baseline to Week 26 (percentage of total hemoglobin), Baseline, Week 26. Exenatide Once Weekly: -1.47; Insulin Glargine: -1.31. |
| NCT02229383Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus | Exenatide | 464 | Change in HbA1c From Baseline to Week 28 (Percentage of HbA1c), Baseline to Week 28. Exenatide: -0.96; Placebo: -0.22. |
| PIONEER 10Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes | Dulaglutide | 458 | Number of Treatment-emergent Adverse Events (TEAEs) (Events), Weeks 0-57. Oral Semaglutide 3 mg: 330; Oral Semaglutide 7 mg: 350; Oral Semaglutide 14 mg: 324; Dulaglutide 0.75 mg: 178. |
| DUAL II ChinaA Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD) | Liraglutide | 453 | Change in HbA1c (Percentage point of HbA1c), Week 0, week 26. Insulin Degludec/Liraglutide: -1.93; Insulin Degludec: -1.06. |
| NCT01617434The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes | Liraglutide | 451 | Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 26 (percentage of glycosylated haemoglobin), Week 0 to Week 26. Liraglutide: -1.30; Placebo: -0.11. |
| NCT03861039A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes | Tirzepatide | 443 | Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration (Participants), Baseline through Week 52. 5 mg Tirzepatide: 0; 10 mg Tirzepatide: 1; 15 mg Tirzepatide: 1. |
| DUAL IIIThe Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy | Liraglutide | 438 | Change in Glycosylated Haemoglobin (HbA1c) From Baseline (Randomisation, Visit 2) (percentage of glycosylated haemoglobin), Week 0, week 26. Insulin Degludec/Liraglutide + Oral Anti Diabetic Drugs (OADs): -1.32; Liraglutide or Exenatide + OADs: -0.37. |
| DUALIVThe Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy | Liraglutide | 435 | Change in Glycosylated Haemoglobin (HbA1c) (percentage of glycosylated haemoglobin), Week 0, Week 26. IDegLira: -1.45; Placebo: -0.46. |
| NCT00935532Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes Mellitus | Exenatide | 427 | Change in HbA1c From Baseline to Endpoint (Week 26) (percentage of total hemoglobin), Baseline, Week 26. Exenatide Once Weekly: -1.11; Insulin Glargine: -0.68. |
| AWARD-10A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus | Dulaglutide | 424 | Change From Baseline in Hemoglobin A1c (HbA1c) at 24 Weeks (Treatment-regimen Estimand) (percentage of HbA1c), Baseline, Week 24. 1.5 mg Dulaglutide: -1.34; 0.75 mg Dulaglutide: -1.21; Placebo: -0.54. |
| NCT00781937Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance | Liraglutide | 422 | Mean Percentage Change in Fasting Body Weight From Baseline (percentage), Week 0, week 56. Lira 3.0 mg: -6.11; Placebo: -0.05. |
| DUAL VIA Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms | Liraglutide | 420 | Change From Baseline in HbA1c (percentage), Week 0, week 32. IDegLira (1WT): -2.01; IDegLira: -2.02. |
| DUALTM IXA Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus | Liraglutide | 420 | See the trial's page: several measures or groups. |
| BEGINComparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin | Liraglutide | 413 | Change From Baseline in HbA1c (%) (Glycosylated Haemoglobin) (percentage of glycosylated haemoglobin), week 0, week 26. IDeg: 0.10; IDeg + Liraglutide: -0.74; IDeg + IAsp OD: -0.39. |
| DUAL IIA Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes | Liraglutide | 413 | Change From Baseline in HbA1c (Glycosylated Haemoglobin) (percentage of glycosylated haemoglobin), Week 0, week 26. IDegLira: -1.90; IDeg: -0.89. |
| NCT05064735Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis | Semaglutide | 407 | Percentage Change in Body Weight (Percentage change in body weight), Baseline (week 0), end of treatment (week 68). Semaglutide 2.4 mg: -14.2; Placebo: -2.5. |
| ACHIEVE-JA Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes | Orforglipron | 401 | Number of Participants With Treatment Emergent Adverse Events (TEAEs) (Participants), Baseline to Week 54. 3 mg Orforglipron: 107; 12 mg Orforglipron: 114; 36 mg Orforglipron: 118. |
| STEP 6STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity | Semaglutide | 401 | Change in Body Weight (%) (Percentage change), Baseline (week 0), week 68. Semaglutide 1.7 mg: -9.9; Semaglutide 2.4 mg: -13.4; Placebo: -1.9. |
| NCT00393718Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes | Liraglutide | 400 | Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment (percentage of total haemoglobin), after 24 weeks of treatment. Liraglutide: 6.99; Glibenclamide: 7.50. |
| SUSTAIN 5Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes | Semaglutide | 397 | Change in HbA1c (Glycosylated Haemoglobin) (percentage of glycosylated hemoglobin), Week 0, week 30. Semaglutide 0.5 mg: -1.45; Semaglutide 1.0 mg: -1.85; Placebo: -0.09. |
| SCALE InsulinEffect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin | Liraglutide | 396 | See the trial's page: several measures or groups. |
| NCT01468181A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus | Dulaglutide | 394 | Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) (percentage of participants), Baseline through 52 Weeks. LY2189265 + SU: 85.5; LY2189265 + BG: 83.6; LY2189265 + a-GI: 70.8; LY2189265 + TZD: 80.3; LY2189265 + Glinides: 73.2. |
| NCT05478252A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes | Semaglutide | 388 | Change in Glycosylated Haemoglobin (HbA1c) (Percentage of glycosylated haemoglobin), From baseline (week 0) to end of treatment (week 28). Semaglutide J: -1.7; Semaglutide B: -1.6. |
| SUSTAIN1Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes | Semaglutide | 388 | Change in HbA1c (Glycosylated Haemoglobin) (Percentage of HbA1c), Week 0, week 30. Semaglutide 0.5 mg: -1.47; Semaglutide 1.0 mg: -1.56; Placebo: -0.00. |
| DURATION-NEO-1Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes | Exenatide | 377 | Change in HbA1c (Glycosylated Hemoglobin) From Baseline to Week 28 (Percentage of total hemoglobin), Baseline to Week 28. Experimental: Exenatide QWS Suspension: -1.39; Active Comparator: Exenatide BID: -1.02. |
| STEP7Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity. | Semaglutide | 375 | Change From Baseline in Body Weight (Percentage [%]) (Percentage change), Baseline (week 0), week 44. Semaglutide 2.4 mg: -12.5; Placebo: -3.6. |
| DURATION-NEO-2Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus | Exenatide | 365 | Change in HbA1c (Glycosylated Hemoglobin) From Baseline to Week 28 (percentage of total hemoglobin), Baseline to Week 28. Experimental: Exenatide: -1.13; Active Comparator: Sitagliptin: -0.75; Placebo Comparator: Placebo: -0.40. |
| NCT01512108Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD Alone | Liraglutide | 363 | See the trial's page: several measures or groups. |
| NCT01584232A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus | Dulaglutide | 361 | Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks (percentage of HbA1c), Baseline, 26 weeks. LY2189265 + OAM: -1.44; Insulin Glargine + OAM: -0.90. |
| NCT01557166Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea | Liraglutide | 359 | Change From Baseline in Apnoea-hypopnoea Index (AHI) (events/hour), Week 0, Week 32. Liraglutide 3.0 mg: -12.22; Placebo: -6.08. |
| NCT01664247The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification | Liraglutide | 346 | Change From Baseline in Glycosylated Haemoglobin (HbA1c) (%) (percentage of glycosylated haemoglobin), Week 0, week 26. IDeg: -0.99; Placebo: -0.07. |
| NCT00560417Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and Exenatide | Exenatide | 339 | See the trial's page: several measures or groups. |
| STEP 8Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity | Semaglutide | 338 | Change From Baseline (Week 0) to Week 68 in Body Weight (%) (Semaglutide 2.4 mg Versus Liraglutide 3.0 mg) (Percentage of body weight), Baseline (week 0), week 68. Semaglutide 2.4 mg: -16.4; Liraglutide 3.0 mg: -6.4. |
| PIONEER 5Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment | Semaglutide | 324 | See the trial's page: several measures or groups. |
| SUSTAINA Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes | Semaglutide | 308 | Number of Treatment Emergent Adverse Events (TEAEs) (Number of events), Weeks 0-30. Semaglutide 0.5 mg: 228; Semaglutide 1.0 mg: 197; Sitagliptin: 186. |
| OASIS 4Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range | Semaglutide | 307 | Percentage Change in Body Weight (Percentage change in body weight), Baseline (week 0), end of treatment (week 64). Oral Semaglutide 25 mg: -14.4; Placebo: -2.5. |
| STEP 5Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity | Semaglutide | 304 | See the trial's page: several measures or groups. |
| NCT00308139Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1) | Exenatide | 303 | Change in HbA1c From Baseline to Week 30 (percentage of total hemoglobin), Day -3, Week 30. Exenatide Once Weekly: -1.87; Exenatide Twice Daily: -1.54. |
| NCT02964247LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors. | Liraglutide | 303 | See the trial's page: several measures or groups. |
| SUSTAIN 9Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus | Semaglutide | 302 | Change in HbA1c (Percentage of HbA1c), Week 0, week 30. Semaglutide 1.0 mg: -1.6; Placebo: -0.2. |
| AWARD-8Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8) | Dulaglutide | 300 | Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at 24 Weeks (percent change of HbA1c), Baseline, 24 Weeks. Dulaglutide: -1.38; Placebo: -0.11. |
| AWARD-9A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes | Dulaglutide | 300 | Change From Baseline to 28 Weeks in Hemoglobin A1c (HbA1c) (percentage of change), Baseline, 28 Weeks. Dulaglutide + Insulin Glargine: -1.44; Placebo + Insulin Glargine: -0.67. |
| AWARD-CHN3A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes | Dulaglutide | 291 | Change From Baseline in Hemoglobin A1c (HbA1c) (Percentage of HbA1c), Baseline, Week 28. 1.5 mg Dulaglutide: -2.03; Placebo: -1.08. |
| SCALE IBTEffect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting | Liraglutide | 282 | See the trial's page: several measures or groups. |
| NCT01620489Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment | Liraglutide | 279 | Estimated Mean From the Statistical Model and Standard Deviation From Observed Data For Change From Baseline to Week 26 in HbA1c (%) (Glycosylated Haemoglobin) (percentage (%)), Week 0, Week 26. Lira 1.8 mg: -1.05; Placebo: -0.38. |
| RISE AdultRISE Adult Medication Study | Liraglutide | 267 | Insulin Sensitivity, M/I (x 10-5 mmol/kg/min per pmol/L), 3-months after a medication washout. Metformin Alone: 3.53; Glargine Followed by Metformin: 3.38; Placebo: 3.63; Liraglutide + Metformin: 3.49. |
| SURMOUNT-JA Study of Tirzepatide (LY3298176) in Participants With Obesity Disease | Tirzepatide | 267 | Mean Percent Change in Body Weight (Percent change), Baseline, 72 Weeks. 10 mg Tirzepatide: -17.8; 15 mg Tirzepatide: -22.7; Placebo: -1.7. |
| NCT00395746Effect of Liraglutide in Combination With Sulfonylurea (SU) on Blood Glucose Control in Subjects With Type 2 Diabetes | Liraglutide | 264 | Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment (percentage of total haemoglobin), after 24 weeks of treatment. 0.6 mg + SU: 7.02; 0.9 mg + SU: 6.75; SU Mono: 8.02. |
| NCT00765817Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus | Exenatide | 261 | Change in Glycosylated Hemoglobin (HbA1c) (percentage of hemoglobin), baseline and 30 weeks. Exenatide Arm: -1.71; Placebo Arm: -1.00. |
| NCT01572740Efficacy and Safety of Liraglutide in Combination With Insulin Therapy Compared to Insulin Alone in Japanese Subjects With Type 2 Diabetes | Liraglutide | 257 | Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 16 (percentage of glycosylated haemoglobin), Week 0, Week 16. Lira + Insulin: -1.73; Placebo + Insulin: -0.43. |
| SURPASS-CN-INSA Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes | Tirzepatide | 257 | Mean Change From Baseline in HbA1c (Tirzepatide 10 or 15 Milligram [mg]) (millimoles per mole (mmol/mol)), Baseline, Week 40. 10 mg Tirzepatide: -26.1; 15 mg Tirzepatide: -25.9; Placebo: -9.96. |
| NCT00877890A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5) | Exenatide | 254 | Change in HbA1c From Baseline to Week 24 (percentage of total hemoglobin), Day 1, Week 24. Exenatide Once Weekly: -1.57; Exenatide Twice Daily: -0.90. |
| NCT02918279Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity | Liraglutide | 251 | Change in BMI SDS (Week 0, Week 56) (SDS score), Week 0, week 56. Liraglutide 3.0 mg: -0.25; Placebo: -0.02. |
| PIONEER 9Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes | Liraglutide | 243 | See the trial's page: several measures or groups. |
| STEP12A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range | Semaglutide | 242 | Change in Body Weight (%) (Percentage change in body weight), Baseline (week 0), end of treatment (week 44). Semaglutide 2.4 mg: -12.2; Placebo: -2.2. |
| ATTAIN-JA Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease | Orforglipron | 238 | Percent Change From Baseline in Body Weight at Week 72 (percent change), Baseline, Week 72. Placebo QD: -0.63; 6 mg Orforglipron QD: -5.90; 12 mg Orforglipron QD: -8.69; 36 mg Orforglipron QD: -7.93. |
| NCT00360334A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes Patients | Exenatide | 235 | Percent of Patients Who Achieved HbA1c ≤ 7.4% With Minimal Weight Gain (≤ 1kg) (percentage of participants), 26 weeks. Exenatide: 53.4; Insulin Glargine: 19.8. |
| NCT01003184Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 Diabetes | Exenatide | 222 | Percentage of Patients Achieving Glycosylated Hemoglobin (HbA1c) Concentration ≤7.0% With Weight Loss (≥1.0 kg) at Endpoint (Week 26) (Percentage), Baseline, Week 26. Exenatide Once Weekly: 44.1; Insulin Detemir: 11.4. |
| SURMOUNT-CNA Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN) | Tirzepatide | 210 | Mean Percent Change From Baseline in Body Weight (Percent change), Baseline, Week 52. 10 mg Tirzepatide: -14.4; 15 mg Tirzepatide: -19.9; Placebo: -2.4. |
| DUAL II JapanA Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs | Liraglutide | 210 | Change in Glycosylated Haemoglobin (HbA1c) (Percentage of HbA1c), week 0, week 26. Insulin Degludec/Liraglutide: -1.95; Insulin Degludec: -0.65. |
| STEP 10Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes | Semaglutide | 207 | Change in Body Weight (Percentage [%]) (Percentage (%) of body weight), From randomisation (week 0) to end of treatment (week 52). Semaglutide 2.4 mg: -14.4; Placebo: -2.7. |
| NCT05963022A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO) | Tirzepatide | 206 | Change From Baseline in Hemoglobin A1c (HbA1c) (percentage of HbA1c), Baseline, Week 40. 5 mg Tirzepatide: -2.19; 10 mg Tirzepatide: -1.75; 15 mg Tirzepatide: -2.03; Placebo: -0.77. |
| NCT04102189A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity | Semaglutide | 201 | Change in Body Mass Index (BMI) (Percentage [%]) (Percentage change of BMI), Baseline (week 0), week 68. Semaglutide 2.4 mg: -16.2; Placebo: -0.1. |
| OASIS 2Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity | Semaglutide | 201 | Percent Change From Baseline in Body Weight (Percent change of body weight), Baseline (week 0), week 68. Oral Semaglutide 50 mg: -14.9; Oral Semaglutide Placebo: -1.5. |
| NCT00375492Effect on Weight Loss of Exenatide Versus Placebo | Exenatide | 196 | Change From Baseline in Body Weight (kg), Baseline, Week 24. Group A (Exenatide): -6.16; Group B (Placebo): -3.97. |
| NCT03374956Individualized Obesity Pharmacotherapy | Liraglutide | 193 | Change in Total Body Weight (percent change), baseline to 12 weeks. Intervention Group: -7.7; Control Group: -6.5. |
| NCT00577824Efficacy and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s) | Exenatide | 181 | Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 24 (Percentage of hemoglobin), baseline, 24 weeks. 5mcg Exenatide BID: -1.34; 10mcg Exenatide BID: -1.62; Placebo BID: -0.28. |
| NCT00603239Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin | Exenatide | 165 | Change in Glycosylated Hemoglobin (HbA1c) (Percentage), baseline and 26 weeks. Exenatide Twice Daily (BID): -0.84; Placebo: -0.10. |
| AWARD-PEDSA Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes | Dulaglutide | 154 | Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses) at Week 26 (percentage of HbA1C), Baseline, Week 26. Placebo: 0.5; Pooled Dulaglutide: -0.7. |
| NCT01234649Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM) | Liraglutide | 153 | Insulin Secretion-Sensitivity Index (IS-SI) (index), 84 weeks of treatment. Metformin XR Plus Liraglutide: 418.4; Metformin XR Plus Placebo: 333. |
| NCT04998136Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity | Semaglutide | 150 | Change in Body Weight (%) : In-trial Observation Period (Percentage of body weight), Baseline (week 0), end of treatment (week 44). Semaglutide: -16.4; Placebo: -2.6. |
| NCT00856609The Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese Subjects | Exenatide | 150 | Energy Intake (kcal/day), Day 6-7-8 (at baseline) and Day 12-13-14 (3 days after starting study intervention). Exenatide: 1016.1; Placebo: 245.1. |
| NCT05813912A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes | Semaglutide | 148 | See the trial's page: several measures or groups. |
| NCT03737240IDegLira HIGH Trial | Liraglutide | 145 | Change in Hemoglobin A1c (HbA1c) (percentage of HbA1c), Baseline, Week 26. IDegLira: -3.18; Basal-Bolus Insulin: -3.00. |
| NCT00135330An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus | Exenatide | 137 | See the trial's page: several measures or groups. |
| EllipseEfficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes | Liraglutide | 135 | Change in HbA1c (Glycosylated Haemoglobin) (Percentage of HbA1c), Week 0, week 26. Liraglutide 1.8 mg: -0.643; Placebo: 0.415. |
| NCT00753896Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin | Exenatide | 134 | See the trial's page: several measures or groups. |
| PIONEER TEENSA Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes | Semaglutide | 132 | Change From Baseline (Week 0) to Week 26 in Glycosylated Haemoglobin (HbA1c)- Percentage Point (Percentage point), Baseline (Week 0), Week 26. Oral Semaglutide: -1.0; Placebo: -0.3. |
| NCT00658021Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes | Exenatide | 122 | Adjusted Change From Baseline in Glycated Hemoglobin A1c (HbA1c) at Week 28 (percentage (%HbA1c)), Baseline (Day 1) and Week 28. Total Exenatide Twice Daily (EBID): 0.11; Placebo: 0.38. |
| NCT02635386EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS) | Exenatide | 119 | Oral Disposition (Insulin Sensitivity-insulin Secretion) Index (index score), 24 weeks of treatment. Exenatide Once Weekly (EQW ): 471; Dapagliflozin (DAPA): 311; EQW Plus DAPA: 503; Dapagliflozin Plus Glucophage (MET ER): 395; Phentermine /Topiramate (PHEN/ TPM) ER: 545. |
| REMODELA Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial) | Semaglutide | 106 | See the trial's page: several measures or groups. |
| SURPASS-PEDSA Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both | Tirzepatide | 99 | Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg and 10 mg) (percentage of HbA1c), Baseline, Week 30. Pooled Doses of Tirzepatide (5 mg, 10 mg): -2.03; Placebo: -0.23. |
| APPLELiver and Fat Regulation in Overweight Adolescent Girls | Exenatide | 92 | Hepatic Glucose Release (mg/kg/min), Measured up to 4 months from enrollment. Control: 1.85; PCOS Medication Naive: 1.46; PCOS, Medication Naive + Byetta: 1.54; PCOS on COCPs: 1.88; PCOS on Metformin: 1.57. |
| SAXAPCOSLiraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS | Liraglutide | 88 | Absolute Body Weight (BW) (kilogram), 32 weeks of treatment. Liraglutide Pen Injector (Saxenda): 104.7; Placebo Liraglutide Pen Injector: 117.9. |
| NCT01554618Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes | Exenatide | 84 | Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) to Week 24 (Controlled Assessment Period) (percentage (% HbA1c)), Baseline (Week 0) and Week 24. Controlled Assessment Period - Exenatide: -0.36; Controlled Assessment Period - Placebo: 0.49. |
| NCT01753362Liraglutide In Overweight Patients With Type 1 Diabetes | Liraglutide | 84 | See the trial's page: several measures or groups. |
| NCT02889510Study to Assess the Efficacy of Liraglutide in Patients With Type 2 Diabetes Mellitus | Liraglutide | 76 | Changes From Baseline on Measurements of Respiratory Function Defined by Forced Expiratory Volume in 1 Second (FEV1) (% (FEV1)), 7 weeks. Liraglutide: 4.1; Placebo: 4.3. |
| NCT01722266Liraglutide in the Treatment of Type 1 Diabetes Mellitus | Liraglutide | 72 | Change in Mean Weekly Glucose Concentrations (mg/dl), 12 Weeks. Placebo: 1; Liraglutide 1.8mg: -10; Liraglutide 1.2mg: -10; Liraglutide 0.6 mg: -0.3. |
| BARI-STEPSemaglutide 2.4 mg in Patients With Poor Weight-loss | Semaglutide | 70 | Percentage Weight Change (percentage change), Baseline and week 68. Placebo: 0.4; Semaglutide 2.4mg: -18.0. |
| NCT00097500Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes | Exenatide | 69 | Beta-cell Function After 52 Weeks of Therapy (ratio), Baseline (week -2) and 52 weeks. Exenatide Arm: 2.89; Insulin Glargine Arm: 1.15. |
| 1966Liraglutide in Type 1 Diabetes | Liraglutide | 69 | See the trial's page: several measures or groups. |
| NCT01784965Liraglutide and a Calorie Restricted Diet Augments Weight Loss and Decreases Risk of Type 2 Diabetes and CVD. | Liraglutide | 69 | Change in Weight Reported at 14 Weeks (kg), Baseline and 14 weeks. Placebo: -3.3; Liraglutide: -6.8. |
| TEALTreating PCOS With Semaglutide vs Active Lifestyle Intervention | Semaglutide | 60 | Change in Hepatic Fat Fraction (Change in percentage of liver fat), Baseline and 12 weeks. Diet Intervention: -1.41; GLP-1 Intervention: -1.84. |
| NCT00516048An Exploratory Study of the Effect of Treatment Interruption on Safety of Exenatide in Patients With Type 2 Diabetes | Exenatide | 58 | See the trial's page: several measures or groups. |
| NCT02251431Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome | Exenatide | 57 | See the trial's page: several measures or groups. |
| NCT02527200Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome | Liraglutide | 56 | Change in Body Mass Index (BMI) Standard Deviation Score (SDS) From Baseline to 16 Weeks (SDS score), Week 0, Week 16. Part A: Liraglutide: -0.18; Part A: Placebo: -0.18; Part B: Liraglutide: -0.50; Part B: Placebo: -0.48; Part A+B: Liraglutide: -0.33; Part A+B: Placebo: -0.29. |
| NCT00516074A Study to Assess the Effect of Exenatide Treatment on Mean 24-Hour Heart Rate in Patients With Type 2 Diabetes | Exenatide | 54 | See the trial's page: several measures or groups. |
| NCT00620282The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus | Liraglutide | 49 | Change in Acetylcholine (ACh)-Mediated Forearm Blood Flow (FBF) (mL/100 mL/min), week 0, week 12. Lira 1.8: 4.244; Placebo: -3.187; Glimepiride: 2.164. |
| NCT03115424Effect of GLP-1 Receptor Agonism After Sleeve Gastrectomy | Liraglutide | 46 | See the trial's page: several measures or groups. |
| ECHOEnergy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity | Exenatide | 42 | Percent Change of Body Mass Index (BMI) as Calculated by the Formula: Body Weight in kg Divided by Height in Meters². (percent change from baseline), From baseline to 36 weeks. Exenatide Once Weekly Extended-release: 1.7; Matching Placebo: 3.5. |
| BELIEVEBinge Eating Liraglutide Intervention | Liraglutide | 36 | Binge Episodes (objective binge episodes per week), baseline and 17 weeks (or last observation carried forward). Liraglutide: -3.97; Placebo: -2.50. |
| DUALA Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification | Liraglutide | 31 | Change From Baseline in HbA1c (Glycosylated Haemoglobin) (Percentage of glycosylated haemoglobin), Week 0, week 26. IDegLira: -0.43; IDegLira + IAsp: -0.14. |
| NCT02518945Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes | Liraglutide | 26 | Absolute Change After 12 Weeks From Baseline in Mean HbA1c With Addition of Dapagliflozin Compared to Placebo. (% HbA1c), 12 weeks. Placebo: 0; Active Drugs: -0.66. |
| NCT05891496A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease | Semaglutide | 23 | Change in Gene Expression Assessed by Single-cell Ribonucleic Acid Sequencing (scRNAseq) (Cells in Cerebrospinal Fluid [CSF]) (Differentially expressed genes), Baseline (week 0), week 12. Semaglutide: 41.25; Placebo: 21.00. |
| NCT00679042Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol | Exenatide | 21 | See the trial's page: several measures or groups. |
| NCT04466566A Study to Evaluate the Effect of Genetic Variation on Beta-cell Function During Fasting and Hyperglycemia in Nondiabetics | Liraglutide | 21 | See the trial's page: several measures or groups. |
| NCT01847313The Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Diabetic Kidney Disease | Liraglutide | 20 | MCP-1:Creatinine Ratio in Urine (ng/mmol), Up to 26 weeks. Liraglutide: 27.9; Control: 24.3. |
| NCT01937598Antidiabetic Effects of Adding a DPP-4 Inhibitor to Pre-Existing Treatment With an Incretin Mimetic in Patients With T2D | Liraglutide | 16 | Incremental Area Under the Plasma Glucose (BG) Concentration-time Profile (AUC) ([mg*min/dL]), 0 to 300 min post mixed meal test. Sitagliptin: 5678; Placebo: 5557. |
| RAISE-KTEffect of Subcutaneous Semaglutide on Kidney Transplant Candidacy | Semaglutide | 15 | Kidney Transplant Eligibility (Participants), Ascertained at the end of 9 months. Semaglutide: 3; Placebo: 2. |
| IIH EVOLVEA Trial to Determine the Efficacy and Safety of Presendin in IIH | Exenatide | 14 | See the trial's page: several measures or groups. |
| NAFLDRole of Exenatide in NASH-a Pilot Study | Exenatide | 8 | See the trial's page: several measures or groups. |
| NCT05788965Semaglutide in CFRD | Semaglutide | 8 | See the trial's page: several measures or groups. |
| NCT02516657Liraglutide in Adolescents With Type 1 Diabetes | Liraglutide | 5 | See the trial's page: several measures or groups. |
Updated automatically
What just changed in the registry
- TrialNew Semaglutide study registered: A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity
- TrialSemaglutide study now completed (was unknown): The Effect of Different Diets on Arterial Stiffness in Obese Patients on Semaglutide
- TrialTirzepatide study now recruiting (was not yet recruiting): AI-Assisted Lifestyle Intervention Versus Tirzepatide for Obesity and Newly Diagnosed Type 2 Diabetes
- TrialTirzepatide study now recruiting (was not yet recruiting): A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes
- TrialExenatide study now completed (was active, not recruiting): Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol
- TrialSemaglutide study now recruiting (was not yet recruiting): Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes
- TrialNew Liraglutide study registered: The Effect of Liraglutide on Body Weight, Body Composition, Ectopic Lipid Accumulation and Insulin Sensitivity in Subjects With Overweight or Obesity Without Diabetes
- TrialNew Semaglutide study registered: Brain and Obesity Longitudinal Development: Neurobiological Mechanisms of Semaglutide Treatment of Adolescent Obesity
Written from each source's own record as it changes. Every change on GLPcompare
GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.